EE200000391A - Triasiiniühendid kesknärvisüsteemihäirete raviks - Google Patents

Triasiiniühendid kesknärvisüsteemihäirete raviks

Info

Publication number
EE200000391A
EE200000391A EEP200000391A EEP200000391A EE200000391A EE 200000391 A EE200000391 A EE 200000391A EE P200000391 A EEP200000391 A EE P200000391A EE P200000391 A EEP200000391 A EE P200000391A EE 200000391 A EE200000391 A EE 200000391A
Authority
EE
Estonia
Prior art keywords
treatment
nervous system
central nervous
system disorders
triazine compounds
Prior art date
Application number
EEP200000391A
Other languages
English (en)
Estonian (et)
Inventor
Patrick Healy Mark
Stuart Nobbs Malcolm
Punjabhai Shah Gita
Cox Brian
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000391A publication Critical patent/EE200000391A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200000391A 1997-12-22 1998-12-18 Triasiiniühendid kesknärvisüsteemihäirete raviks EE200000391A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726987.2A GB9726987D0 (en) 1997-12-22 1997-12-22 Compounds
PCT/EP1998/008273 WO1999032462A1 (en) 1997-12-22 1998-12-18 Triazine compounds for treatment of cns disorders

Publications (1)

Publication Number Publication Date
EE200000391A true EE200000391A (et) 2002-02-15

Family

ID=10823992

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000391A EE200000391A (et) 1997-12-22 1998-12-18 Triasiiniühendid kesknärvisüsteemihäirete raviks

Country Status (34)

Country Link
US (2) US6265405B1 (no)
EP (1) EP1042304A1 (no)
JP (1) JP2001526275A (no)
KR (1) KR20010024800A (no)
CN (1) CN1284951A (no)
AP (1) AP2000001846A0 (no)
AR (1) AR014146A1 (no)
AU (1) AU753874B2 (no)
BR (1) BR9814495A (no)
CA (1) CA2315620A1 (no)
CO (1) CO5011066A1 (no)
EA (1) EA200000561A1 (no)
EE (1) EE200000391A (no)
GB (1) GB9726987D0 (no)
GT (1) GT199800203A (no)
HN (1) HN1998000193A (no)
HR (1) HRP20000419A2 (no)
HU (1) HUP0100611A3 (no)
ID (1) ID25449A (no)
IL (1) IL136867A0 (no)
IS (1) IS5542A (no)
JO (1) JO2065B1 (no)
MA (1) MA26587A1 (no)
NO (1) NO20003211L (no)
NZ (1) NZ505254A (no)
PA (1) PA8465101A1 (no)
PE (1) PE20000063A1 (no)
PL (1) PL341392A1 (no)
SK (1) SK9592000A3 (no)
SV (1) SV1998000151A (no)
TR (1) TR200001970T2 (no)
WO (1) WO1999032462A1 (no)
YU (1) YU39600A (no)
ZA (1) ZA9811725B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
EP1458386B1 (en) * 2001-12-27 2007-04-18 Ortho-McNeil Pharmaceutical, Inc. Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder
AU2003260336C1 (en) * 2002-07-29 2008-05-29 Glaxo Group Limited Sustained release formulations comprising lamotrigine
US20040213842A1 (en) * 2003-01-30 2004-10-28 Dynogen Pharmaceuticals, Inc. Methods of treating gastrointestinal tract disorders using sodium channel modulators
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
DE10332472A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Tinnitus
AU2004266494B2 (en) * 2003-08-25 2010-04-08 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
US20060115865A1 (en) * 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
PE20180951A1 (es) 2015-08-17 2018-06-11 Japan Tobacco Inc Compuestos de hidroxitriazina y usos medicos de los mismos
ES2770143T3 (es) * 2018-02-13 2020-06-30 Fis Fabbrica Italiana Sintetici Spa Nuevo procedimiento eficiente para la preparación de sitagliptina
CN114796146B (zh) * 2022-04-28 2023-03-28 上海奥科达医药科技股份有限公司 一种拉莫三嗪的缓释制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637688A (en) 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
DE3062603D1 (en) 1979-06-01 1983-05-11 Wellcome Found 3,5-diamino-1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
DD151309A5 (de) 1979-06-01 1981-10-14 Wellcome Found Verfahren zur herstellung von substituierten aminotriazinen
DE3069556D1 (en) 1979-08-16 1984-12-06 Wellcome Found Solid pharmaceutical formulation containing substitued phenyl-triazines
GB8328757D0 (en) 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012312D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012316D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9203483D0 (en) 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
HRP930964B1 (en) 1992-06-12 2000-06-30 Wellcome Found Therapeutic triazine compounds and the use thereof
WO1994014780A1 (en) 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
GB9305692D0 (en) 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
US5866597A (en) 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9426448D0 (en) 1994-12-30 1995-03-01 Wellcome Found Process
FR2741879A1 (fr) 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament

Also Published As

Publication number Publication date
HN1998000193A (es) 2000-04-05
AU753874B2 (en) 2002-10-31
YU39600A (sh) 2002-11-15
WO1999032462A1 (en) 1999-07-01
PE20000063A1 (es) 2000-02-16
CO5011066A1 (es) 2001-02-28
MA26587A1 (fr) 2004-12-20
ID25449A (id) 2000-10-05
SK9592000A3 (en) 2001-03-12
EP1042304A1 (en) 2000-10-11
CN1284951A (zh) 2001-02-21
HUP0100611A3 (en) 2003-03-28
IS5542A (is) 2000-06-20
SV1998000151A (es) 1999-07-05
CA2315620A1 (en) 1999-07-01
HRP20000419A2 (en) 2000-12-31
GB9726987D0 (en) 1998-02-18
US6265405B1 (en) 2001-07-24
IL136867A0 (en) 2001-06-14
KR20010024800A (ko) 2001-03-26
TR200001970T2 (tr) 2001-01-22
NO20003211D0 (no) 2000-06-21
BR9814495A (pt) 2000-10-10
NZ505254A (en) 2002-06-28
AP2000001846A0 (en) 2000-06-30
US6465461B1 (en) 2002-10-15
JO2065B1 (en) 2000-05-21
HUP0100611A2 (hu) 2001-09-28
PA8465101A1 (es) 2000-09-29
AR014146A1 (es) 2001-02-07
JP2001526275A (ja) 2001-12-18
GT199800203A (es) 2000-06-14
AU2414799A (en) 1999-07-12
NO20003211L (no) 2000-08-21
PL341392A1 (en) 2001-04-09
ZA9811725B (en) 2000-06-27
EA200000561A1 (ru) 2001-04-23

Similar Documents

Publication Publication Date Title
EE04280B1 (et) Imidasopürimidiinid ja imidasopüridiinid neuroloogiliste häirete käitlemiseks
DE69925571D1 (de) Sulphonamid-derivate zur behandlung von störungen des zentralnervensystems
IS5113A (is) Notkun antagónista CB1-viðtaka til meðhöndlunar löngunartruflana
DK0769947T3 (da) Indolinonforbindelser til behandling af sygdom
NO20005864D0 (no) Quinasoler til behandling av hjernesvulst
DK0830864T3 (da) Kombinationsbehandling til behandling af psykoser
NO20004688L (no) Terapi ved østrogenassosierte lidelser
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
EE200000391A (et) Triasiiniühendid kesknärvisüsteemihäirete raviks
FI980387A0 (fi) Foerfarande foer att foerhindra bildning av utfaellningar i svartlutsindunstare
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
FI942400A7 (fi) Lääkeaine hermosairauksia vastaan
DK0935598T3 (da) 5-heteroatom-alkylsubstituerede 3-oxopyrido(1,2-a)benzimidazol-4-carboxamidderivater egnede til behandling af sygdomme i centralnervesystemet
NO991734D0 (no) Pyrazolinoner for behandling av potensforstyrrelser
BR9712030A (pt) Uso de benzopiranÄis para o tratamento de desordens neurolÄgicas
ATE287718T1 (de) Benzenesulfonamide derivate in kombination mit beta-blockern zur behandlung von störungen des autonomen nervensystems
IS1919B (is) Bensamíð til að meðhöndla taugahrörnunarsjúkdóma
ID21920A (id) 4-6-fluoro-(1h)-indol-3-il-1,2,3,6-tetrahidropirin tersubstitusi untuk pengobatan gangguan cns
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
DK1011678T3 (da) Anvendelse af mecamylamin til behandling af nikotin-responsive neuropsykiatriske lidelser
NO20012538D0 (no) Anvendelse av N-substituerte azabicycloalkanderivater for behandling av forstyrrelser i sentralnervesystemet
UA25221A (uk) Спосіб лікуваhhя розладів цеhтральhої hервової системи
IL136949A0 (en) 1,4-diazacycloheptane derivatives for the treatment of neurological disorders
IL121597A0 (en) Novel optically pure amines for the treatment of central nervous system disorders